Edwards Lifesciences stock holds near $90 after earnings
Published on 08/29/2026 at 11:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Edwards Lifesciences stock (US28176E1082) held near $90 after the company reported $1.74 billion in revenue and $0.78 in earnings per share for the quarter ended July 23, 2026. The same update showed revenue growth of 13.6% from a year earlier and EPS $0.04 above consensus. ad hoc news report on Edwards Lifesciences earnings
Revenue and profit both improved
The latest quarterly figures put revenue at $1.74 billion and EPS at $0.78 for the period ended July 23, 2026. Revenue was $0.04 billion above the $1.70 billion consensus estimate, while EPS was $0.04 above the $0.74 forecast.
That is a clean beat on both lines, and the comparison is material because revenue rose 13.6% from the same quarter a year earlier, when the company posted $0.67 in EPS. Guidance for third-quarter 2026 was set at $0.71 to $0.77 per share, and full-year 2026 guidance was $2.95 to $3.05 per share.
Trading stays elevated
Market data in the same update showed the shares at $89.92 on August 27, 2026, with a daily decline of 0.95% and a market cap of $51.888 billion. A separate quote snapshot placed the stock at $89.50 with a last update at 7:54 p.m. on August 27, 2026.
The stock has also been moving against a wider valuation backdrop: one market note put the price-to-earnings ratio at 51.83 and the 200-day moving average at $84.99. That leaves the shares trading above the long-term average while still close to the $90 area.
TAVR remains central
The company's core business still centers on transcatheter aortic valve replacement, where procedural volume and pricing are the key drivers behind the revenue mix. Recent coverage also pointed to TAVR sales of $1.26 billion in the quarter, which helps explain why investors are still focused on the structural heart franchise.
What the stock is saying
Edwards Lifesciences stock is trading on a mix of earnings momentum, strong guidance and a valuation that still looks demanding versus the broader market. The next leg for the shares will depend on whether the company can keep revenue growth and margin support intact through the rest of 2026.
More on Edwards Lifesciences
More on Edwards Lifesciences stock and its quarterly update from August 28, 2026.
Fact box
Company: Edwards Lifesciences Corporation
ISIN: US28176E1082
Ticker: EW
Exchange: NYSE
Price (as of August 27, 2026, 7:54 p.m. ET): $89.50 USD
Market cap: $51.888 billion (as of August 27, 2026)
Sector / Industry: Health Care / Medical Devices
Index membership: S&P 500
